Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Despite recent advances, chemoimmunotherapy remains a standard for fit previously untreated chronic lymphocytic leukaemia patients. Lenalidomide had activity in early monotherapy trials, but tumour lysis and flare proved major obstacles in its development. We combined lenalidomide in increasing dose...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ann Hematol
Autori principali: Egle, Alexander, Steurer, Michael, Melchardt, Thomas, Weiss, Lukas, Gassner, Franz Josef, Zaborsky, Nadja, Geisberger, Roland, Catakovic, Kemal, Hartmann, Tanja Nicole, Pleyer, Lisa, Voskova, Daniela, Thaler, Josef, Lang, Alois, Girschikofsky, Michael, Petzer, Andreas, Greil, Richard
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2018
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097797/
https://ncbi.nlm.nih.gov/pubmed/29862437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-018-3380-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi